P J Borgstein1, S Meijer, P J van Diest. 1. Department of Surgical Oncology, University Hospital, Vrije Universiteit, Amsterdam, The Netherlands.
Abstract
BACKGROUND: In-transit metastases and satellite lesions are manifestations of locoregional cutaneous recurrence that are characteristic of malignant melanoma. They are the result of tumor cell emboli entrapped in the dermal lymphatics between the primary tumor and the regional lymph node basin. Histopathological features of lymphatic invasion were investigated to determine the possibility of predicting locoregional cutaneous metastases in melanoma patients. METHODS: In a prospective study, 258 patients with clinical stage I melanoma underwent wide local excision and sentinel node biopsy. Nodal metastases were found in 53 (21%) patients. Of 29 patients (11.2%) who had developed recurrences to date, 17 (6.6%) had locoregional cutaneous metastases. All surgical specimens were examined with particular attention to histopathological signs of lymphatic vascular invasion or microscopic satellites. RESULTS: Unequivocal signs of lymphatic invasion were observed in 14 of 258 patients (5.4%), and 13 (93%) of these patients subsequently developed in-transit metastases, after a median interval of 10 months. The primary melanoma was located on the extremities in seven patients. The median Breslow thickness was 2.5 mm, and 5 showed ulceration. In 244 of 258 patients (94.6%), there were no signs of lymphatic invasion. To date, only four patients (1.6%) have had a locoregional cutaneous recurrence, occurring after a median interval of 29 months. All four of these patients had ulcerative melanomas on an extremity, with a median thickness of 4.0 mm. The presence of lymphatic invasion was significantly related to early locoregional cutaneous relapse (P < .0001). CONCLUSIONS: Locoregional cutaneous recurrence appears to be highly predictable in the presence of histopathological signs of lymphatic invasion. Lymphatic invasion is an important prognostic parameter and should be included as a stratification criterion when selecting patients for adjuvant (locoregional) therapy.
BACKGROUND: In-transit metastases and satellite lesions are manifestations of locoregional cutaneous recurrence that are characteristic of malignant melanoma. They are the result of tumor cell emboli entrapped in the dermal lymphatics between the primary tumor and the regional lymph node basin. Histopathological features of lymphatic invasion were investigated to determine the possibility of predicting locoregional cutaneous metastases in melanomapatients. METHODS: In a prospective study, 258 patients with clinical stage I melanoma underwent wide local excision and sentinel node biopsy. Nodal metastases were found in 53 (21%) patients. Of 29 patients (11.2%) who had developed recurrences to date, 17 (6.6%) had locoregional cutaneous metastases. All surgical specimens were examined with particular attention to histopathological signs of lymphatic vascular invasion or microscopic satellites. RESULTS: Unequivocal signs of lymphatic invasion were observed in 14 of 258 patients (5.4%), and 13 (93%) of these patients subsequently developed in-transit metastases, after a median interval of 10 months. The primary melanoma was located on the extremities in seven patients. The median Breslow thickness was 2.5 mm, and 5 showed ulceration. In 244 of 258 patients (94.6%), there were no signs of lymphatic invasion. To date, only four patients (1.6%) have had a locoregional cutaneous recurrence, occurring after a median interval of 29 months. All four of these patients had ulcerative melanomas on an extremity, with a median thickness of 4.0 mm. The presence of lymphatic invasion was significantly related to early locoregional cutaneous relapse (P < .0001). CONCLUSIONS: Locoregional cutaneous recurrence appears to be highly predictable in the presence of histopathological signs of lymphatic invasion. Lymphatic invasion is an important prognostic parameter and should be included as a stratification criterion when selecting patients for adjuvant (locoregional) therapy.
Authors: Markwin G Statius Muller; Paul A M van Leeuwen; Paul J van Diest; Rik Pijpers; Robert J Nijveldt; Ronald J C L M Vuylsteke; Sybren Meijer Journal: World J Surg Date: 2002-09-26 Impact factor: 3.352
Authors: Travis E Grotz; Svetomir N Markovic; Lori A Erickson; William S Harmsen; Marianne Huebner; David R Farley; Barbara A Pockaj; John H Donohue; Franklin H Sim; Clive S Grant; Sanjay P Bagaria; Thomas C Shives; Charles M Balch; James W Jakub Journal: Mayo Clin Proc Date: 2011-06 Impact factor: 7.616
Authors: J Gregory McKinnon; Emma C Starritt; Richard A Scolyer; William H McCarthy; John F Thompson Journal: Ann Surg Date: 2005-02 Impact factor: 12.969
Authors: Emanuelle M Rizk; Angelina M Seffens; Megan H Trager; Michael R Moore; Larisa J Geskin; Robyn D Gartrell-Corrado; Winston Wong; Yvonne M Saenger Journal: Am J Clin Dermatol Date: 2020-02 Impact factor: 7.403
Authors: Edmund K Bartlett; Meera Gupta; Jashodeep Datta; Phyllis A Gimotty; DuPont Guerry; Xiaowei Xu; David E Elder; Brian J Czerniecki; Douglas L Fraker; Giorgos C Karakousis Journal: Ann Surg Oncol Date: 2013-11-21 Impact factor: 5.344
Authors: G S Mijnhout; O S Hoekstra; A van Lingen; P J van Diest; H J Adèr; A A Lammertsma; R Pijpers; S Meijer; G J J Teule Journal: J Clin Pathol Date: 2003-04 Impact factor: 3.411
Authors: Katharine A Yao; Eddy C Hsueh; Richard Essner; Leland J Foshag; Leslie A Wanek; Donald L Morton Journal: Ann Surg Date: 2003-11 Impact factor: 12.969
Authors: Matthew C Perez; John T Miura; Syeda Mahrukh Hussnain Naqvi; Youngchul Kim; Amanda Holstein; Daniel Lee; Amod A Sarnaik; Jonathan S Zager Journal: Ann Surg Oncol Date: 2018-10-08 Impact factor: 5.344